Tiger BioSciences Targets Booming Home Healthcare Market with New At-Home Wound Care Kits

CONSHOHOCKEN, PA – April 01, 2026 – Tiger BioSciences, a prominent player in the regenerative medicine field, today announced its official entry into the consumer-facing home healthcare space with the launch of carePAC™, a line of pre-configured wound care convenience kits. The new product aims to simplify the often complex and stressful process of managing wounds at home, addressing a critical need for patients transitioning from clinical care.

The carePAC™ kits bundle all the necessary components for a dressing change into a single, sealed, and organized pouch. This design is intended to empower patients and their caregivers, reduce confusion, and improve adherence to treatment plans prescribed by healthcare providers.

"Wound care does not stop when a patient leaves the clinic," said Garrett Grinsfelder, President of Tiger Wound Care, in a statement accompanying the announcement. "With carePAC™, we are helping bridge the gap between the clinical setting and the home by delivering convenient, pre-configured kits that simplify the dressing change process and support better continuity of care."

This launch marks a significant strategic step for the Conshohocken-based company, extending its expertise from advanced clinical therapies to accessible at-home solutions.

Addressing a Critical Gap in Home Healthcare

The challenges of managing chronic or post-surgical wounds at home are well-documented. Patients and family caregivers frequently struggle with obtaining the correct array of supplies, understanding the proper sequence for a dressing change, and adhering to a consistent schedule. This can lead to anxiety, improper care, and an increased risk of complications like infection, which may result in costly hospital readmissions.

Research highlights numerous hurdles, from the scarcity of specialized wound care nurses available for home visits to the simple but profound confusion patients face when confronted with a long list of individual supplies to purchase. Products like carePAC™ are designed to directly address these pain points. By providing a curated, all-in-one system, the company aims to eliminate the guesswork involved in at-home wound management.

"carePAC™ was developed with both providers and patients in mind," noted Oliver Burckhardt, Co-CEO of Tiger BioSciences. "By pre-configuring the components required for dressing changes, we can help streamline care delivery, reduce patient confusion, and ultimately support improved wound management outcomes."

This focus on simplifying the patient experience aligns with a broader industry shift towards patient-centric models that prioritize ease of use and empowerment, recognizing that better adherence often leads to better clinical results.

A Strategic Move in a Booming Market

Tiger BioSciences' launch of carePAC™ is not just a response to patient needs but also a calculated move into a rapidly expanding market. The global chronic wound care market is projected to swell to US$24 billion by 2032, fueled by an aging population and the rising prevalence of chronic diseases like diabetes and obesity, which are major contributors to hard-to-heal wounds.

Simultaneously, healthcare systems worldwide are aggressively promoting a shift from expensive inpatient hospital stays to more cost-effective home-based care. This trend creates a substantial market opportunity for products that can safely and effectively support complex medical treatments outside of a clinical facility. The homecare settings segment of the wound care market is expected to see robust growth, with a projected compound annual growth rate of nearly 7%.

This product launch appears to be the culmination of a longer-term strategy. In February 2025, Tiger BioSciences acquired HealPACK surgical dressing solutions, a company that specialized in post-surgery kits shipped directly to patients. The development of carePAC™ suggests a refinement and expansion of that initial foray into the direct-to-patient home care market, leveraging Tiger's vertically integrated structure, which spans from tissue processing to product distribution.

Navigating a Complex and Competitive Landscape

While innovative, Tiger BioSciences enters a field with established players. Companies like Medline already offer similar "starter kits" designed to guide caregivers, and various medical suppliers provide home delivery of wound care products. The key differentiator for carePAC™ will likely be its integration with Tiger's broader portfolio of regenerative medicine and its ability to create highly specific, protocol-driven kits.

The regulatory environment for such products is also becoming more stringent. The U.S. Food and Drug Administration (FDA) has been increasing its scrutiny of wound dressings, particularly those containing antimicrobial agents, often classifying them as Class II or Class III medical devices requiring rigorous review. This means manufacturers must provide substantial evidence of safety and effectiveness to gain and maintain market access.

Furthermore, securing reimbursement is crucial for widespread adoption. In the United States, Medicare Part B and private insurers typically cover medically necessary wound care supplies, but the process is governed by strict documentation requirements. For a patient to receive a product like carePAC™, a physician must document the wound's specific characteristics and justify the need for the prescribed supplies. The success of carePAC™ will depend not only on its convenience for patients but also on its ability to fit seamlessly into these existing regulatory and reimbursement frameworks.

Redefining the Future of Wound Management

The introduction of solutions like carePAC™ reflects a fundamental evolution in how the healthcare system approaches wound management. By decentralizing care and empowering patients with user-friendly tools, the industry is moving away from a purely clinician-driven model. This shift has the potential to improve efficiency, lower costs, and enhance the quality of life for millions of people managing chronic health conditions.

Standardized kits can also help ensure a consistent standard of care, mitigating the variability that can occur when caregivers with limited training are left to their own devices. For home health agencies, such products can streamline supply management and help ensure their nurses are compliant with evidence-based protocols, freeing up valuable time to focus on patient assessment and education.

As Tiger BioSciences continues to build out its portfolio, which includes advanced cellular products and aesthetic technologies, the launch of carePAC™ solidifies its commitment to providing a full spectrum of solutions across the entire continuum of care. This strategy, which combines high-tech regenerative therapies for clinical use with practical, accessible products for the home, positions the company to be a comprehensive partner to both providers and the patients they serve.